Federal regulators close an investigation into Baxter’s Chinese operations without taking any action against the healthcare giant. Baxter (NYSE:BAX) closed the books on a federal bribery investigation after regulators dropped the probe without finding wrongdoing, the company announced. The investigation was part of an industry-wide foreign bribery inquiry in which regulators from the SEC and the DOJ asked medical device makers to voluntarily review their own overseas operations.
Help employers find you! Check out all the jobs and post your resume.
